Serum Levels of Kisspeptin Are Elevated in Patients with Pancreatic Cancer

Sven H Loosen; Mark Luedde; Georg Lurje; Martina Spehlmann; Pia Paffenholz; Tom Florian Ulmer; Frank Tacke; Mihael Vucur; Christian Trautwein; Ulf P Neumann; Tom Luedde; Christoph Roderburg

doi:10.1155/2019/5603474

Serum Levels of Kisspeptin Are Elevated in Patients with Pancreatic Cancer

Sven H Loosen, Mark Luedde, Georg Lurje, Martina Spehlmann, Pia Paffenholz, Tom Florian Ulmer, Frank Tacke, Mihael Vucur, Christian Trautwein, Ulf P Neumann, Tom Luedde^*, Christoph Roderburg

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Pancreatic adenocarcinoma (PDAC) still represents a devastating disease associated with a very limited survival. Novel biomarkers allowing an early diagnosis as well as an optimal selection of suitable treatment options for individual patients are urgently needed to improve the dismal outcome of PDAC patients. Recently, alterations of Kisspeptin serum levels, a member of the adipokine family, were described in various types of cancers. However, the role of circulating Kisspeptin as a biomarker in PDAC patients is poorly defined. In this study, we measured Kisspeptin serum levels in a cohort of 128 prospectively enrolled PDAC patients undergoing surgical resection as well as 36 healthy controls. Kisspeptin concentrations were elevated in PDAC patients compared to control samples. Nevertheless, Kisspeptin serum levels were independent of tumor-related factors such as the tumor grading, TNM stage, or clinical features such as the ECOG performance status. Finally, in our analysis, neither preoperative nor postoperative Kisspeptin levels turned out as a significant predictor of overall survival after tumor resection. In conclusion, our data suggest that Kisspeptin concentrations are altered in PDAC patients but do not allow to predict patients' outcome after resection of PDAC.

Original language	English
Article number	5603474
Pages (from-to)	1-8
Number of pages	8
Journal	Disease Markers
Volume	2019
DOIs	https://doi.org/10.1155/2019/5603474
Publication status	Published - 2019

Access to Document

10.1155/2019/5603474

Cite this

@article{1d54f8e7a91940828b54b92ea96b65bd,

title = "Serum Levels of Kisspeptin Are Elevated in Patients with Pancreatic Cancer",

abstract = "Pancreatic adenocarcinoma (PDAC) still represents a devastating disease associated with a very limited survival. Novel biomarkers allowing an early diagnosis as well as an optimal selection of suitable treatment options for individual patients are urgently needed to improve the dismal outcome of PDAC patients. Recently, alterations of Kisspeptin serum levels, a member of the adipokine family, were described in various types of cancers. However, the role of circulating Kisspeptin as a biomarker in PDAC patients is poorly defined. In this study, we measured Kisspeptin serum levels in a cohort of 128 prospectively enrolled PDAC patients undergoing surgical resection as well as 36 healthy controls. Kisspeptin concentrations were elevated in PDAC patients compared to control samples. Nevertheless, Kisspeptin serum levels were independent of tumor-related factors such as the tumor grading, TNM stage, or clinical features such as the ECOG performance status. Finally, in our analysis, neither preoperative nor postoperative Kisspeptin levels turned out as a significant predictor of overall survival after tumor resection. In conclusion, our data suggest that Kisspeptin concentrations are altered in PDAC patients but do not allow to predict patients' outcome after resection of PDAC.",

author = "Loosen, {Sven H} and Mark Luedde and Georg Lurje and Martina Spehlmann and Pia Paffenholz and Ulmer, {Tom Florian} and Frank Tacke and Mihael Vucur and Christian Trautwein and Neumann, {Ulf P} and Tom Luedde and Christoph Roderburg",

note = "Copyright {\textcopyright} 2019 Sven H. Loosen et al.",

year = "2019",

doi = "10.1155/2019/5603474",

language = "English",

volume = "2019",

pages = "1--8",

journal = "Disease Markers",

issn = "0278-0240",

publisher = "IOS Press",

}

TY - JOUR

T1 - Serum Levels of Kisspeptin Are Elevated in Patients with Pancreatic Cancer

AU - Loosen, Sven H

AU - Luedde, Mark

AU - Lurje, Georg

AU - Spehlmann, Martina

AU - Paffenholz, Pia

AU - Ulmer, Tom Florian

AU - Tacke, Frank

AU - Vucur, Mihael

AU - Trautwein, Christian

AU - Neumann, Ulf P

AU - Luedde, Tom

AU - Roderburg, Christoph

PY - 2019

Y1 - 2019

N2 - Pancreatic adenocarcinoma (PDAC) still represents a devastating disease associated with a very limited survival. Novel biomarkers allowing an early diagnosis as well as an optimal selection of suitable treatment options for individual patients are urgently needed to improve the dismal outcome of PDAC patients. Recently, alterations of Kisspeptin serum levels, a member of the adipokine family, were described in various types of cancers. However, the role of circulating Kisspeptin as a biomarker in PDAC patients is poorly defined. In this study, we measured Kisspeptin serum levels in a cohort of 128 prospectively enrolled PDAC patients undergoing surgical resection as well as 36 healthy controls. Kisspeptin concentrations were elevated in PDAC patients compared to control samples. Nevertheless, Kisspeptin serum levels were independent of tumor-related factors such as the tumor grading, TNM stage, or clinical features such as the ECOG performance status. Finally, in our analysis, neither preoperative nor postoperative Kisspeptin levels turned out as a significant predictor of overall survival after tumor resection. In conclusion, our data suggest that Kisspeptin concentrations are altered in PDAC patients but do not allow to predict patients' outcome after resection of PDAC.

AB - Pancreatic adenocarcinoma (PDAC) still represents a devastating disease associated with a very limited survival. Novel biomarkers allowing an early diagnosis as well as an optimal selection of suitable treatment options for individual patients are urgently needed to improve the dismal outcome of PDAC patients. Recently, alterations of Kisspeptin serum levels, a member of the adipokine family, were described in various types of cancers. However, the role of circulating Kisspeptin as a biomarker in PDAC patients is poorly defined. In this study, we measured Kisspeptin serum levels in a cohort of 128 prospectively enrolled PDAC patients undergoing surgical resection as well as 36 healthy controls. Kisspeptin concentrations were elevated in PDAC patients compared to control samples. Nevertheless, Kisspeptin serum levels were independent of tumor-related factors such as the tumor grading, TNM stage, or clinical features such as the ECOG performance status. Finally, in our analysis, neither preoperative nor postoperative Kisspeptin levels turned out as a significant predictor of overall survival after tumor resection. In conclusion, our data suggest that Kisspeptin concentrations are altered in PDAC patients but do not allow to predict patients' outcome after resection of PDAC.

U2 - 10.1155/2019/5603474

DO - 10.1155/2019/5603474

M3 - Article

C2 - 31772690

SN - 0278-0240

VL - 2019

SP - 1

EP - 8

JO - Disease Markers

JF - Disease Markers

M1 - 5603474

ER -